Is tolvaptan (a vasopressin V2 receptor antagonist) effective in the management of isovolumic and hypervolaemic hypernatremia?
¿El tolvaptán, un antagonista de los receptores de la vasopresina V2, ¿es un tratamiento eficaz para la hiponatremia euvolémica e hipervolémica?
F. Ortiz
Leído
3811
Vecesse ha leído el artículo
401
Total PDF
3410
Total HTML
Información del artículo
ISSN: 20132514Idioma original: Inglés
Datos actualizados diariamente
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 11 | 59 | 0 | 59 |
| 2025 10 | 46 | 0 | 46 |
| 2025 9 | 62 | 0 | 62 |
| 2025 8 | 34 | 0 | 34 |
| 2025 7 | 50 | 0 | 50 |
| 2025 6 | 74 | 0 | 74 |
| 2025 5 | 101 | 0 | 101 |
| 2025 4 | 56 | 0 | 56 |
| 2025 3 | 112 | 0 | 112 |
| 2025 2 | 65 | 0 | 65 |
| 2025 1 | 52 | 0 | 52 |
| 2024 12 | 47 | 0 | 47 |
| 2024 11 | 39 | 0 | 39 |
| 2024 10 | 37 | 0 | 37 |
| 2024 9 | 65 | 0 | 65 |
| 2024 8 | 58 | 0 | 58 |
| 2024 7 | 42 | 0 | 42 |
| 2024 6 | 60 | 0 | 60 |
| 2024 5 | 43 | 0 | 43 |
| 2024 4 | 42 | 0 | 42 |
| 2024 3 | 28 | 3 | 31 |
| 2024 2 | 25 | 10 | 35 |
| 2024 1 | 30 | 6 | 36 |
| 2023 12 | 18 | 8 | 26 |
| 2023 11 | 28 | 6 | 34 |
| 2023 10 | 24 | 13 | 37 |
| 2023 9 | 23 | 13 | 36 |
| 2023 8 | 29 | 5 | 34 |
| 2023 7 | 29 | 8 | 37 |
| 2023 6 | 20 | 5 | 25 |
| 2023 5 | 38 | 8 | 46 |
| 2023 4 | 17 | 3 | 20 |
| 2023 3 | 21 | 0 | 21 |
| 2023 2 | 25 | 5 | 30 |
| 2022 1 | 18 | 0 | 18 |
| 2022 12 | 31 | 2 | 33 |
| 2022 11 | 22 | 3 | 25 |
| 2022 10 | 24 | 2 | 26 |
| 2022 9 | 33 | 2 | 35 |
| 2022 8 | 39 | 3 | 42 |
| 2022 7 | 20 | 0 | 20 |
| 2022 6 | 21 | 6 | 27 |
| 2022 5 | 17 | 0 | 17 |
| 2022 4 | 17 | 1 | 18 |
| 2022 3 | 25 | 2 | 27 |
| 2022 2 | 19 | 4 | 23 |
| 2021 1 | 16 | 0 | 16 |
| 2021 12 | 27 | 5 | 32 |
| 2021 11 | 19 | 0 | 19 |
| 2021 10 | 16 | 5 | 21 |
| 2021 9 | 26 | 0 | 26 |
| 2021 8 | 20 | 1 | 21 |
| 2021 7 | 28 | 5 | 33 |
| 2021 6 | 9 | 1 | 10 |
| 2021 5 | 16 | 0 | 16 |
| 2021 4 | 31 | 10 | 41 |
| 2021 3 | 20 | 1 | 21 |
| 2021 2 | 18 | 7 | 25 |
| 2020 1 | 21 | 6 | 27 |
| 2020 12 | 7 | 1 | 8 |
| 2020 11 | 24 | 3 | 27 |
| 2020 10 | 6 | 1 | 7 |
| 2020 9 | 6 | 3 | 9 |
| 2020 8 | 24 | 5 | 29 |
| 2020 7 | 10 | 1 | 11 |
| 2020 6 | 16 | 5 | 21 |
| 2020 5 | 18 | 4 | 22 |
| 2020 4 | 19 | 4 | 23 |
| 2020 3 | 19 | 8 | 27 |
| 2020 2 | 27 | 3 | 30 |
| 2020 1 | 26 | 5 | 31 |
| 2019 12 | 21 | 5 | 26 |
| 2019 11 | 19 | 3 | 22 |
| 2019 10 | 4 | 1 | 5 |
| 2019 9 | 12 | 1 | 13 |
| 2019 8 | 8 | 4 | 12 |
| 2019 7 | 9 | 2 | 11 |
| 2019 6 | 20 | 3 | 23 |
| 2019 5 | 14 | 0 | 14 |
| 2019 4 | 18 | 13 | 31 |
| 2019 3 | 7 | 0 | 7 |
| 2019 2 | 8 | 5 | 13 |
| 2019 1 | 7 | 0 | 7 |
| 2018 12 | 32 | 16 | 48 |
| 2018 11 | 13 | 8 | 21 |
| 2018 10 | 19 | 15 | 34 |
| 2018 9 | 20 | 4 | 24 |
| 2018 8 | 8 | 8 | 16 |
| 2018 7 | 11 | 9 | 20 |
| 2018 6 | 6 | 10 | 16 |
| 2018 5 | 14 | 12 | 26 |
| 2018 4 | 11 | 4 | 15 |
| 2018 3 | 15 | 6 | 21 |
| 2018 2 | 14 | 6 | 20 |
| 2018 1 | 10 | 5 | 15 |
| 2017 12 | 12 | 9 | 21 |
| 2017 11 | 9 | 3 | 12 |
| 2017 10 | 7 | 8 | 15 |
| 2017 9 | 12 | 3 | 15 |
| 2017 8 | 12 | 6 | 18 |
| 2017 7 | 4 | 3 | 7 |
| 2017 6 | 9 | 5 | 14 |
| 2017 5 | 8 | 3 | 11 |
| 2017 4 | 12 | 1 | 13 |
| 2017 3 | 6 | 2 | 8 |
| 2017 2 | 7 | 2 | 9 |
| 2016 1 | 4 | 1 | 5 |
| 2016 12 | 12 | 2 | 14 |
| 2016 11 | 17 | 5 | 22 |
| 2016 10 | 21 | 5 | 26 |
| 2016 9 | 41 | 1 | 42 |
| 2016 8 | 75 | 0 | 75 |
| 2016 7 | 63 | 0 | 63 |
| 2016 6 | 65 | 0 | 65 |
| 2016 5 | 59 | 0 | 59 |
| 2016 4 | 39 | 0 | 39 |
| 2016 3 | 30 | 0 | 30 |
| 2016 2 | 29 | 0 | 29 |
| 2015 1 | 33 | 0 | 33 |
| 2015 12 | 73 | 0 | 73 |
| 2015 11 | 25 | 0 | 25 |
| 2015 10 | 25 | 0 | 25 |
| 2015 9 | 23 | 0 | 23 |
| 2015 8 | 18 | 0 | 18 |
| 2015 7 | 33 | 0 | 33 |
| 2015 6 | 4 | 0 | 4 |
| 2015 5 | 49 | 0 | 49 |
Mostrar todo
